Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
36Kr Exclusive | Post-2000s medical doctorate creates a wearable anti-snoring device, receives exclusive investment from Shunwei
Ask AI · How does Ran Xinxin’s medical background shape innovation in snoring devices?
Author | Qiao Yujie
Editor | Yuan Silai
Hardened Crypto has learned that Shenzhen Yehe Technology Co., Ltd. (hereinafter referred to as “Yehe Technology”) recently announced the completion of a ten-million-yuan angel round of financing, exclusively invested by Shunwei Capital, with Shendu Capital serving as the financial advisor for this round. The funds will mainly be used for core product research and development, accelerating the extension of “medical technology into consumer scenarios.”
Yehe Technology was founded in 2025 and is headquartered in Shenzhen. Its first product focuses on the sleep breathing track, developing lightweight, comfortable, and non-positional wearable neck devices for snoring populations and obstructive sleep apnea (OSA) patients.
The company’s founder, Ran Xinxin, has a medical background from two top hospitals, West China Hospital and Ruijin Hospital, and is pursuing a Ph.D. in medicine at Shanghai Jiao Tong University, with long-term research in the interdisciplinary field of medical engineering. In clinical practice, Ran Xinxin discovered the pain point that patients lack consumer-grade snoring medical products, and then went to start a business in Shenzhen, successfully creating the first prototype in an incubator at Shenzhen Science and Technology Innovation College.
In an interview with Hardened Crypto, Ran Xinxin pointed out, “The intersection of medicine and engineering itself has considerable friction; when it comes to the consumer side, how to balance the solutions becomes even more complex.” In her view, there is a significant difference between medical thinking and product thinking, and many clinical solutions have value in being redone—“We need to understand what users need; clinical devices weighing dozens of pounds are not suitable for everyone.”
Currently, the most effective clinical treatment device for OSA is a ventilator, but due to discomfort and inconvenience, patients are resistant. Consumer-grade products on the market, such as smart anti-snoring pillows, electrical stimulation pillows, oral appliances, and nasal strips, although improved in comfort, have limited therapeutic intervention effects. Overall, there is currently no product on the market that achieves a good balance between comfort and effectiveness.
It is reported that Yehe Technology’s first consumer-grade OSA medical product will be released within 2026. Based on an already small-scale clinically validated principle, this product aims to create a wearable device capable of imperceptible intervention during sleep cycles, capable of real-time monitoring of snoring, blood oxygen, heart rate, and other physiological indicators, enabling personalized intervention.
Regarding commercialization, Yehe Technology will adopt a dual-track strategy. Ran Xinxin stated that initially, the product will be marketed directly as a health consumer product, with a focus on North America and other overseas regions; meanwhile, clinical trials will be conducted simultaneously. The company plans to gradually build medical barriers in its long-term strategy, and in the future, it may establish an independent product line to upgrade the product to medical-grade standards.
Investor perspective:
Shunwei Capital Partner Zhang Zhijian said: “We invested in Yehe, not only because we are optimistic about the OSA track but also because of Dr. Ran herself. As a medical doctor rooted in frontline healthcare, she can step out of a purely medical perspective and demonstrate very keen consumer insights, with strong empathy for patients and consumers. Dr. Ran combines the rational thinking of a medical Ph.D. with emotional resonance for consumers, making her a perfect founder with product management qualities. She is a founder we are willing to accompany for the long term.”